$INSM

Adsett Roger sold $242K of INSM

Adsett Roger (Chief Operating Officer) sold 2,370 shares of INSMED Inc (INSM) at $102.27 ($0.24M total) on 2026-06-03.

Original reporting
SEC EDGAR · Adsett Roger
Published Jun 5, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INSM
Bearish
medium confidence
Mentioned
$INSM
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMBearishLow
01

Why it matters

Traders may treat it as a mild sentiment input, but without earnings, trial, or deal updates it should not drive a standalone thesis.

02

Market read

A single officer sale disclosed after execution; potential short-term sentiment drag but no fundamental catalyst provided.

03

What to watch

No context on total insider holdings, prior sales cadence, or whether other insiders/large holders acted around the same time.

Relevance 6/10Novelty 6/10Timing: Filed June 5; sale executed June 3.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the COO.

Company-level read

Ticker impact

$INSMBearishMedium confidence
Context

INSMED COO Adsett Roger sold 2,370 shares in an open-market transaction disclosed via SEC Form 4 on June 3.

Expected impact

Likely limited near-term impact; could add slight selling pressure or raise caution among short-term traders.

Evidence & confidence

The filing is a disclosed officer sale, not a planned 10b5-1 plan, but the article lacks size vs. float context or any accompanying company-specific news.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio rebalancing; absence of a 10b5-1 plan doesn’t necessarily imply bearish fundamentals.

Key entities

  • INSMED Inc

    Company whose insider transaction was disclosed (INSM).

  • Adsett Roger

    Chief Operating Officer who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INSMHighAI 8/10

Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business

Insmed (INSM) reported Q2 2026 revenue of $425.5M, up 296% YoY, with net loss narrowing to $13.2M. BRINSUPRI sales reached $309.2M, up 49% QoQ. The company raised full-year BRINSUPRI guidance to $1.25B-$1.40B. Insmed also increased its peak revenue estimate for lead programs to over $14B. Expenses rose due to commercial buildout and R&D spending.

$INSMMedAI 8/10

Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

Insmed (INSM) received approval for BRINSUPRI in Japan, adding to U.S. and European clearances. Shares rose 2.78% to $121.84, with a 30-day return of 23.57% but a YTD decline of 31.21%. Analysts suggest a fair value of $197.14, indicating potential undervaluation, but risks include approval delays and reimbursement challenges.

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$INSMHighAI 9/10

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Inc. (INSM) announced Japan's approval of BRINSUPRI® (brensocatib) for treating non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12+. The approval is based on Phase 3 ASPEN study results showing reduced pulmonary exacerbations and lower lung function decline. BRINSUPRI is now approved in the U.S., Europe, and Japan.

$INSMMed

How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story

Insmed Inc. (INSM) reported a sharply narrowed net loss of $13.24M in Q2 2026, down from $321.69M a year earlier, with loss per share at $0.06 vs. $1.70. The company's H1 2026 net loss also improved to $176.81M from $578.27M, indicating lower cash burn. Insmed's investment narrative focuses on its respiratory portfolio, particularly brensocatib, with guidance projecting $1B in 2026 BRINSUPRI revenue and $450M-$470M from ARIKAYCE. The company aims for $4.1B revenue and $1B earnings by 2029, requi